Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABP1019A
- Development stage
- Phase 1
- Lead developer
- Shanghai Aibo Pharmaceutical Technology
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
ABP1019A is an innovative small molecule tyrosine kinase inhibitor (TKI) developed by Shanghai Aibo Pharmaceutical Technology. It is designed to target multiple receptor tyrosine kinases, including EGFR, FGFR1-4, VEGFR1-3, RET, PDGFR-α, and CSF-1R. The drug is being investigated primarily for the treatment of advanced solid tumors. Clinical studies have focused on evaluating its safety, tolerability, pharmacokinetics (PK), and preliminary efficacy in patients with advanced malignant neoplasms. As of 2025, it has reached Phase 2 clinical development[1][2][7].
- Other names
- ABP1019AABP-1019AABP 1019A
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)EGFR (Epidermal growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on ABP1019A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABP1019A.